Replies to post #6727 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

I feel your excitement.
I'm willing to take matters one data readout at a time.
It's all about the data.
As far as Chronic Cough
It can't go without mentioning:

About Chronic Cough

A chronic (Persistent) cough is a cough lasting eight weeks or longer in adults, or four weeks in children. Chronic cough can interrupt sleep, cause exhaustion and in severe cases can cause serious vomiting, light-headedness and rib fractures.

A dry, non-productive cough is a very common symptom of IPF. At least 70%-85% of patients with IPF have a dry cough, which can often get worse on exertion.

According to a research report from IndustryARC™ the cough remedies market size is estimated to be $11.40Bn, in 2018, growing at a CAGR of 6.64% during 2019-2024. Pleasant taste and easy intake of oral syrups are among the key factors driving the global cough remedies market. Some traditional cough remedies include drinking honey, bromelain and bacterial microbes. Further, some new generation cough remedies include corticosteroids, bronchodilators and antibiotics.

Currently there is no approved treatment for this condition.

Reference:
https://www.globenewswire.com/news-release/2019/12/09/1957730/0/en/Algernon-Pharmaceuticals-Selects-NP-120-Ifenprodil-for-its-Lead-Phase-2-Trial-for-Idiopathic-Pulmonary-Fibrosis-and-Chronic-Cough.html


NP-120 (Ifenprodil) may become the 1st US FDA approved Chronic Cough drug in all the universe.

Algernauts >`



/////AMG